2024
GP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistryTIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarray
2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaBrain metastasesPrimary tumorTumor microenvironmentDigital spatial profilingCell carcinomaActivation protein expressionInflammatory macrophage markersRCC brain metastasesInnate immune activatorsNormal kidney samplesProgressive stagesExtracranial metastasesTim-3Immune checkpointsImmune dysfunctionImmune activationRCC metastasisLonger survivalImmune activatorsMacrophage markersTreatment responseSeparate cohortTissue microarrayMetastatic samplesUtility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue
Sardana R, Abi‐Raad R, Adeniran A, Cai G. Utility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue. Cytopathology 2023, 34: 597-602. PMID: 37534757, DOI: 10.1111/cyt.13283.Peer-Reviewed Original ResearchConceptsParathyroid tissueFine-needle aspirationPTH casesClinicopathological characteristicsCytomorphological featuresThyroid lesionsThinPrep slidesFine needle aspiration diagnosisNeck soft tissuePatients' clinicopathological characteristicsNeedle aspiration diagnosisNegative predictive valueClinical suspicionStudy cohortPathology databaseRetrospective studyDiagnostic challengeDifferential diagnosisInstitutional experienceNeedle aspirationCytological diagnosisFNA casesAspiration diagnosisPredictive valueAdjunct testGermline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Caulfield J, Aizenbud L, Perdigoto A, Meffre E, Jilaveanu L, Michalek D, Rich S, Aizenbud Y, Adeniran A, Herold K, Austin M, Kluger H. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer 2023, 11: e006570. PMID: 36898736, PMCID: PMC10008335, DOI: 10.1136/jitc-2022-006570.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsInsulin-dependent diabetesImmune checkpoint inhibitorsType 1 diabetesCheckpoint inhibitorsControl patientsSevere immune-related adverse eventsImmunotherapy-treated patientsCheckpoint inhibitor therapyIslet cell destructionPotential predictive biomarkersIslet cell functionWhole-exome sequencingICI exposureAdverse eventsGermline genetic variantsInhibitor therapyPatient selectionTreatment regimensCancer patientsPredictive biomarkersGeneral populationPatientsDiabetesSame drugDiagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry
Meiklejohn K, Hrones M, Wang M, Prasad M, Cai G, Adeniran A, Gilani S. Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry. Cytopathology 2023, 34: 219-224. PMID: 36825365, DOI: 10.1111/cyt.13222.Peer-Reviewed Original Research
2019
Agreement on endoscopic ultrasonography‐guided tissue specimens: Comparing a 20‐G fine‐needle biopsy to a 25‐G fine‐needle aspiration needle among academic and non‐academic pathologists
van Riet PA, Cahen DL, Biermann K, Hansen B, Larghi A, Rindi G, Fellegara G, Arcidiacono P, Doglioni C, Decarli N, Iglesias‐Garcia J, Abdulkader I, Iglesias H, Kitano M, Chikugo T, Yasukawa S, van der Valk H, Nguyen N, Ruszkiewicz A, Giovannini M, Poizat F, van der Merwe S, Roskams T, Santo E, Marmor S, Chang K, Lin F, Farrell J, Robert M, Bucobo J, Heimann A, Baldaque‐Silva F, Moro C, Bruno M, Attili F, Aslanian H, Adeniran A, Lee J, Petrone M, Bories E, Scapa E, Buscaglia J, Wu M. Agreement on endoscopic ultrasonography‐guided tissue specimens: Comparing a 20‐G fine‐needle biopsy to a 25‐G fine‐needle aspiration needle among academic and non‐academic pathologists. Digestive Endoscopy 2019, 31: 690-697. PMID: 31290176, PMCID: PMC6900144, DOI: 10.1111/den.13424.Peer-Reviewed Original Research
2016
Changing Pathology of the Thoracic Aorta From Acute to Chronic Dissection Literature Review and Insights
Peterss S, Mansour AM, Ross JA, Vaitkeviciute I, Charilaou P, Dumfarth J, Fang H, Ziganshin BA, Rizzo JA, Adeniran AJ, Elefteriades JA. Changing Pathology of the Thoracic Aorta From Acute to Chronic Dissection Literature Review and Insights. Journal Of The American College Of Cardiology 2016, 68: 1054-1065. PMID: 27585511, DOI: 10.1016/j.jacc.2016.05.091.Peer-Reviewed Original ResearchConceptsAortic dilationType B dissectionCalcium channel blockersFalse lumen patencyLoss of mobilityAortic enlargementB dissectionAortic dissectionChronic stageFalse lumenIntimal flapSurgical interventionAortic growthThoracic aortaChronic stateLumen patencyWall destructionDissectionHigh gradeTemporal courseEarly rapid growthTemporal remodelingCurrent knowledgeDilationCellular levelRacial disparities in renal cell carcinoma: a single‐payer healthcare experience
Mafolasire A, Yao X, Nawaf C, Suarez‐Sarmiento A, Chow W, Zhao W, Corley D, Hofmann JN, Purdue M, Adeniran AJ, Shuch B. Racial disparities in renal cell carcinoma: a single‐payer healthcare experience. Cancer Medicine 2016, 5: 2101-2108. PMID: 27228559, PMCID: PMC4884637, DOI: 10.1002/cam4.755.Peer-Reviewed Original ResearchConceptsDisease-specific survivalRenal cell carcinomaBlack patientsIndependent predictorsSurgical treatmentWhite patientsCell carcinomaRacial disparitiesKaiser Permanente Northern California systemWorse disease-specific survivalCox proportion hazard modelAdvanced American Joint CommitteePapillary renal cell carcinomaKaplan-Meier methodProportion hazard modelAmerican Joint CommitteeLarger tumor sizeCase-control studyHealthcare systemSingle-payer healthcare systemSingle healthcare systemSignificant racial disparitiesOverall survivalPatient demographicsDifferent comorbiditiesGenomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-2175. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellCell DedifferentiationDNA Mismatch RepairDNA-Binding ProteinsExomeFemaleGenes, p53HumansKidney NeoplasmsLoss of HeterozygosityMaleMiddle AgedMutationNuclear ProteinsOncogenesPolymorphism, Single NucleotidePrognosisTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseConceptsClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSarcomatoid elementsCarcinomatous elementsCell carcinomaSomatic single nucleotide variantsVon Hippel-Lindau tumor suppressorPoor-prognosis cancerTreatment of patientsTumor protein p53 (TP53) mutationsMismatch repair deficiencyRich interaction domain 1ASarcomatoid featuresPoor prognosisUnknown pathogenesisPolybromo-1TP53 mutationsP53 mutationsSarcomatoid transformationPan-cancer genesExome sequencingTumorsRepair deficiencyProtein 1
2010
Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases
Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, Sprenkle P, Gupta A, Taylor J, Bernstein M, Adeniran A, Tickoo SK, Reuter VE, Russo P. Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases. Journal Of Urology 2010, 185: 37-42. PMID: 21074196, PMCID: PMC3437930, DOI: 10.1016/j.juro.2010.08.084.Peer-Reviewed Original ResearchConceptsRenal vein invasionRenal cell carcinoma casesVein invasionInvasion groupCarcinoma casesCareful pathological assessmentMultivariate Cox modelOverall survival rateAmerican Joint CommitteeCancer (AJCC) staging systemRisk of recurrencePrognostic equivalencePrognostic impactTumor characteristicsAdverse prognosisRadical nephrectomyRecurrence rateVascular invasionStaging systemNephrectomy specimenPathological assessmentCox modelPatientsJoint CommitteeSurvival rate